Embolotherapy Market Analysis and Forecast to 2031: By Product (Embolization Coil, Embolic Agents, Detachable Balloons, Embolic Plug Systems, Support Devices), Application (Oncology, Peripheral Vascular Devices, Urology & Nephrology, Neurology, GIT Disord

Embolotherapy Market Analysis and Forecast to 2031: By Product (Embolization Coil, Embolic Agents, Detachable Balloons, Embolic Plug Systems, Support Devices), Application (Oncology, Peripheral Vascular Devices, Urology & Nephrology, Neurology, GIT Disorders), Procedures (Transcatheter Arterial Embolization, Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy, Transarterial Chemoembolization), End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), and Region

The global Embolotherapy market was valued at USD 3.8 billion in 2021 and it is anticipated to grow up to USD 7.7 billion by 2031, at a CAGR of 7.3% during the forecast period.


Embolotherapy is the process of obstructing arteries with a device (such as a balloon catheter) in order to treat or stop uncontrollable bleeding. Utilizing this technique, tumors are reduced, and bleeding is controlled. It is an endovascular procedure that attempts to stop bleeding by restricting aberrant blood arteries. Embolotherapy is mostly used to treat cervical uprooted pregnancy, postpartum situations, and pelvic tract hemorrhage.


This treatment has shown promise in the management of iatrogenic solid organ, vascular, and non-operative organ damage, including lesions to the liver, spleen, and kidneys. Embolotherapy is used to treat enlarged uterine fibroids, de vascularize tissues and organs prior to surgery, and eliminate duodenal varices. This necessitates choosing an embolization agent with the required level of vascular blockage permanence.

Global Embolotherapy Market Scope and Report StructureMarket Drivers and Trends

Because more target procedures are being performed on more target patients, the market for embolotherapy devices has been rising steadily over the past ten years. CVD is a major target illness, and research on successful and efficient treatments has focused on it because of its significance and high prevalence. Globally, more than 200 million people have peripheral vascular disorders as of 2017. The prevalence of these disorders increases with age, with the over-80 age group showing a prevalence rate of more than 20%.


The market for embolotherapy devices will likely increase in the near future due to the high success rate and low postoperative complication rate associated with embolotherapy procedures as well as the rising prevalence of liver cancer and hepatocellular carcinoma. The fifth most prevalent cancer in males and the ninth most common in women is liver cancer. Over 840,000 new cases were diagnosed globally in 2018. World Cancer Research Fund, a source. In addition, incidence rates of kidney cancer rose by 42% in the UK over the previous ten years. Male incidence rates were 38 percent, compared to a 44 percent increase in female incidence rates.

Market Restraints and Challenges

The availability of efficient first-level conventional medicines for the management of hemorrhagic disorders such as liver cancer, uterine fibroids, hemorrhagic stroke, and other hemorrhagic conditions is a major market growth inhibitor. For example, therapies like surgery, chemotherapy, and radiation therapy are preferred options in the treatment of cancer due to the high awareness of conventional cancer treatments among the general public, the low adoption of advanced treatment options (especially in developing countries), and the reluctance of oncologists to use alternative therapies.

Global Embolotherapy Market Segmental Overview

The report analyses the global embolotherapy market based on product, application, procedure, end user, and region.

Global Embolotherapy Market by Product

Based on product, it is segmented into embolization coil, embolic agents, detachable balloons, embolic plug systems, and support devices. The embolic agents segment is likely to dominate the market during the forecast period. The market growth of this segment is primarily driven by the surge in the prevalence of hepatocellular carcinoma combined with favorable reimbursement criteria in developed economies. Likewise, new product launches and approvals are further boosting the growth of the market.

Global Embolotherapy Market by Application

Based on application, it is segmented into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The cancer segment is likely to hold the major share of the market. The growing incidences of liver cancer & kidney cancer coupled with the respective adoption of TACE and TARE procedures are boosting the growth of the market.

Global Embolotherapy Market by Procedure

Based on procedure, it is segmented into transcatheter arterial embolization, transcatheter arterial chemoembolization, and transcatheter arterial radioembolization/selective internal radiation therapy. The transcatheter arterial embolization segment is likely to dominate the market during the forecast period. The key factors such as increasing demand for minimally invasive procedures coupled with growing prevalence of chronic diseases and rapid growth in the geriatric population are boosting the growth of the market.

Global Embolotherapy Market by End User

Based on end user, it is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals and clinics segment is likely to dominate the market during the forecast period. The key factors such as growing adoption of minimally invasive surgical procedures (including vascular, urological, and neurological), increasing purchasing power of major healthcare providers across developed countries (owing to the consolidation of healthcare providers), and the greater availability of reimbursements for target procedures in the US and major European countries are the major factors that are expected to drive the demand for embolization devices in hospitals and clinics.

Geographical Analysis of Global Embolotherapy Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific market is expected to hold the majority of the market share during the forecast period. Improving healthcare infrastructure in the region, the large patient population for target diseases, and expanding presence of key market players in the region to grab elevating opportunities offered by these countries are the key factors supporting the market growth in this region.

Major Players in the Global Embolotherapy MarketCOVID-19 Impact:

A decline in sales is being observed in the embolotherapy sector, and this trend is predicted to last until December 2020. This industry's expansion is being hampered by unfavourable changes to the rules and regulations. Cancer patients are more likely to contract COVID-19 infection than healthy persons, according to major regulatory agencies throughout the world (including the CDC, WHO, MHRA, TGA, and EMA). As a result, screening, diagnostic tests, and surgical operations are severely limited or put off at hospitals and cancer treatment facilities. Market disruption for embolotherapy is anticipated as a result.

Recent Developments:

• March 2021, Kaneka has received FDA approval of the Thera Sphere Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma.
• March 2021, Boston Scientific has received US Food and Drug Administration approval of the Thera Sphere Y-90 Glass Microspheres.
• January 2021, Terumo Corporation has the FDA approval of the PMA supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide-neck bifurcation aneurysms.

Frequently Asked Questions

Q1. How big is the Embolotherapy market?Ans. The global Embolotherapy market size was USD 3.8 Billion in 2021 and is anticipated to reach USD 7.7 Billion in 2031, growing at a rate of 7.3% from 2022 to 2031.
Q2. What is the Embolotherapy market growth rate?Ans. The growth rate of the Embolotherapy market is 7.3% from 2022 to 2031.
Q3. Which region holds a major market share for the Embolotherapy market?Ans. North America holds a major market share of the Embolotherapy market in 2021.
Q4. Which segment accounted for the largest Embolotherapy market share?Ans. By end user, the hospitals & clinics segment accounted for the largest Embolotherapy market share.
Q5. Who are the key players in the Embolotherapy market?Ans. The global Embolotherapy market report includes players such as
Q6. What are the factors driving the Embolotherapy market growth?Ans. The major factors driving the growth of the market are expanding applications of Embolotherapy devices.
Q7. What are the key growth strategies of Embolotherapy market players?Ans. The key growth strategies of Embolotherapy market players are product launch and product approval.
Q8. Which region will provide more business opportunities for the Embolotherapy market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the Embolotherapy market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.